Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 19/20 | 0.75 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.58 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17783160 | 1.00 | AAK1 (0.75) | AAK1IMPDH2IMPDH1 | |
| SCHEMBL16371384 | 0.92 | AAK1 (0.67) | AAK1IMPDH2IMPDH1 | |
| SCHEMBL17783157 | 0.92 | AAK1 (0.67) | AAK1IMPDH2IMPDH1 | |
| SCHEMBL17783127 | 0.89 | AAK1 (0.65) | AAK1IMPDH2IMPDH1 | |
| SCHEMBL17783125 | 0.89 | AAK1 (0.65) | AAK1IMPDH2IMPDH1 | |
| SCHEMBL17783170 | 0.88 | AAK1 (0.58) | AAK1IMPDH2 | |
| SCHEMBL17783171 | 0.88 | AAK1 (0.58) | AAK1IMPDH2 | |
| SCHEMBL16371243 | 0.88 | AAK1 (0.82) | AAK1IMPDH2 | |
| SCHEMBL16371993 | 0.88 | AAK1 (0.64) | AAK1IMPDH2IMPDH1 | |
| SCHEMBL17783053 | 0.87 | AAK1 (0.56) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253027-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | AAK1, ADCK1, ANKK1 | AAK1 1/4885IMPDH2 3573/4885IMPDH1 2947/4885 |
| US-10253027-B2 | Aryl lactam kinase inhibitors | AAK1, ADCK1, ANKK1 | AAK1 1/4885IMPDH2 3573/4885IMPDH1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.